Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease.
Shahzad AhmadAdelina OrellanaIsabelle KohlerLutz FrölichItziar de RojasSilvia GilMercè BoadaIsabel HernándezLucrezia HausnerMargot H M BakkerAlfredo Cabrera-SocorroNajaf AminAlfredo RamírezAgustín RuizThomas HankemeierCornelia M Van DuijnPublished in: Alzheimer's research & therapy (2020)
Our findings provide evidence that LPAs may contribute to early AD pathogenesis. Future studies are needed to determine whether LPAs play a role in upstream of AD pathology or are downstream markers of neurodegeneration.